Intellectual property and biotechnology: the U.S. internal experience--Part I.
In the development of biotechnology in the United States, many questions were raised about the appropriateness of applying to this area a traditional robust system of intellectual property rights. Despite these hesitations, the U.S. rejected suggested modifications. This was a mistake, and there is a need to develop a modified system that promotes more of the relevant ethical values.
Brody
Baruch
B
Center for Medical Ethics, Baylor College of Medicine, Houston, TX, USA.
D035843:Biomedical Research / Q000191:economics / Q000266:history / Q000331:legislation & jurisprudence; D001709:Biotechnology / Q000191:economics / Q000266:history* / Q000331:legislation & jurisprudence*; D004274:DNA, Recombinant; D000068817:Epoetin Alfa; D004921:Erythropoietin; D005169:Factor VIII; D035082:Federal Government; D005380:Financing, Government; D005796:Genes; D036281:Genetic Research / Q000191:economics / Q000266:history / Q000331:legislation & jurisprudence; D049673:History, 20th Century; D006801:Humans; D007221:Industry / Q000191:economics / Q000266:history / Q000331:legislation & jurisprudence; D018973:Intellectual Property; D007878:Legislation as Topic; D009316:National Institutes of Health (U.S.); D010067:Ownership / Q000191:economics / Q000266:history* / Q000331:legislation & jurisprudence*; D010330:Patents as Topic / Q000266:history / Q000331:legislation & jurisprudence; D011994:Recombinant Proteins; D018581:Technology Transfer; D014019:Tissue Donors / Q000266:history / Q000331:legislation & jurisprudence; D010959:Tissue Plasminogen Activator; D014481:United States; D014495:Universities
D004274:DNA, Recombinant; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa; D005169:Factor VIII; D010959:Tissue Plasminogen Activator